, Volume 45, Issue 4, pp 279–288 | Cite as

Neurochemical Nature of Cognitive and Emotional Disorders under Conditions of Experimental Diabetes Mellitus

  • Yu. V. Sidorova
  • O. G. Obraztsova
  • D. V. Evdokimov
  • I. I. Abramets
  • A. N. Talalaenko

Experimental diabetes mellitus (EDM) was induced in rats by injections of alloxan (125 mg/kg); this disease was manifested in a rise in the mean level of glucose in the blood from 5.0 to 18.7 mM. On the 4th week of the development of EDM, rats demonstrated increased levels of depression and anxiety and worsening of the processes of formation and reproduction of trained skills. Behavioral modifications were developed against the background of decreases in the amplitudes of NMDA components of field EPSPs (fEPSPs) of pyramidal neurons of the hippocampus and prefrontal neocortex, weakening of the expression of long-term potentiation, and, concurrently, intensified development of long-term depression of synaptic transmission. Injections of insulin (durable action, 2 U per animal) during 2 days resulted in a decrease in the level of glucose in the blood but did not change behavioral and neurochemical disorders typical of EDM. The action of glucose in a high concentration (30 mM) on cerebral slices obtained from intact rats did not influence the relay and plastic properties of glutamatergic synapses of neurons of the hippocampus and neocortex; the action of 0.1 U/ml insulin under these conditions led to an increase in the amplitude of NMDA EPSPcomponents and facilitated the development of plastic phenomena. A blocker of calcium L-type channels, verapamil (20 mg/kg), exerted no significant effect on the relay and plastic properties of synapses between hippocampal and neocortical neurons but partially weakened disorders of behavior and synaptic plasticity under EDM conditions. Such disorders were eliminated by chronic (2 weeks) injections of antidepressants, imipramine and fluoxetine (doses 20 mg/kg), against the background of clearly pronounced hyperglycemia and weakening of functional activity of neuronal NMDA receptors. We hypothesize that a deficiency of activation of insulin receptors of cerebral neurons and hyperglycemia cause a rise in the level of corticosteroids in the blood and brain, and this disturbs synaptic plasticity and behavior. This supposition is based on the ability of calcium channel blockers and (especially) antidepressants to reduce behavioral and neurochemical abnormalities in EDM.


diabetes mellitus depression anxiety training synaptic plasticity NMDA receptors calcium channel blockers antidepressants glucocorticoids 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    P. J. Magistretti, “Brain metabolism,” in: Fundamental Neuroscience, M. J. Zigmond et al. (eds.), Academic, San Diego (1999), pp. 389–413.Google Scholar
  2. 2.
    M. Tsacopulos and P. J. Magistretti, “Metabolic coupling between glia and neurons,” J. Neurosci., 16, No. 3, 877–885 (1996).Google Scholar
  3. 3.
    A. Bacci, C. Verderio, E. Pravettoni, and M. Matteoli, “The role of glial cells in synaptic function,” Philos. Trans. R. Soc. London Ser. B, 354, No. 3, 403–409 (1999).CrossRefGoogle Scholar
  4. 4.
    A. Artola, “Diabetes-, stress-, and ageing-related changes in synaptic plasticity in hippocampus and neocortex – the same metaplastic process?” Eur. J. Pharmacol., 585, No. 1, 153–162 (2008).PubMedCrossRefGoogle Scholar
  5. 5.
    E. A. Northam, D. Renkins, A. Lin, et al., “Central nervous system function in youth with type 1 diabetes 12 years after disease onset,” Diabetes Care, 32, No. 3, 445–452 (2009).PubMedCrossRefGoogle Scholar
  6. 6.
    V. Campanunucci, A. Krishnaswamy, and E. Cooper, “Diabetes depresses synaptic transmission in sympathetic ganglia by inactivating nAChRs through a conserved intracellular cysteine residue,” Neuron, 66, No. 6, 827–834 (2010).CrossRefGoogle Scholar
  7. 7.
    V. A. Caraiscos, R. P. Bonin, J. G. Newell, et al., “Insulin increases the potency of glycine at ionotropic glycine receptors,” Mol. Pharmacol., 71, No. 5, 1277–1286 (2008).CrossRefGoogle Scholar
  8. 8.
    D. R. Johnson, “Diabetes impaired responsiveness to tricyclics,” Pharmacol. Biochem. Behav., 31, No. 4, 807–812 (1988).CrossRefGoogle Scholar
  9. 9.
    Y. Revsin, N. V. Rekers, M. C. Louwe, et al., “Glucocorticoid receptor blockade normalizes hippocampal alterations and cognitive impairment in streptozotocin-induced type 1 diabetes mice,” Neuropsychopharmacology, 34, No. 3, 747–758 (2009).PubMedCrossRefGoogle Scholar
  10. 10.
    R. D. Porsolt, A. Bertin, and M. Jalfre, “ ‘Behavioral despair’ in rats and mice: strain differences and effects of imipramine,” Eur. J. Pharmacol., 51, No. 2, 291–294 (1978).PubMedCrossRefGoogle Scholar
  11. 11.
    S. L. Handley and S. Mithani, “Effects of alphaadrenoceptor agonists and antagonists in a mazeexploration of ‘fear’-motivated behavior,” Naunyn- Schmiedeberg’s Arch. Pharmacol., 327, No. 1, 1–5 (1984).CrossRefGoogle Scholar
  12. 12.
    J. Knoll, K. Kolemen, and B. Knoll, “A method for the elaboration of a non-extinguishable conditioned reflex in the rat,” Acta Physiol. Acad. Sci. Hung., 6, No. 2, 327–345 (1955).Google Scholar
  13. 13.
    I. I. Abramets, D. V. Evdokimov, and A. N. Talalaenko, “Modification of plastic properties and metaplasticity of glutamatergic synapses in the rat cortex and hippocampus under conditions of reserpine-induced behavioral depression,” Neurophysiology, 39, No. 3, 184–190 (2007).CrossRefGoogle Scholar
  14. 14.
    G. J. Biessels, A. Kamal, G. M. Ramakers, et al., “Place learning and hippocampal synaptic plasticity in streptozotocin-diabetic rats: effect of insulin treatment,” Brain Res., 800, No. 1, 125–135 (1998).PubMedCrossRefGoogle Scholar
  15. 15.
    F. Gardoni, A Kamal, C. Bellone, et al., “Effects of streptozotocin-diabetes on the hippocampal NMDA receptor complex in rats,” J. Neurochem., 80, No. 3, 438–447 (2002).PubMedCrossRefGoogle Scholar
  16. 16.
    K.-J. Lin, D. R. Johnson, and G. G. Freund, “LPSdependent suppression of social exploration is augmented in type 1 diabetic mice,” Brain, Behav., Immunol., 21, No. 6, 775–782 (2007).CrossRefGoogle Scholar
  17. 17.
    C. C. Huang, C. C. Lee, and K. S. Hsu, “An investigation into signal transduction mechanisms involved in insulininduced long-term depression in the CA1 region of the hippocampus,” J. Neurochem., 89, No. 1, 217–231 (2004).PubMedCrossRefGoogle Scholar
  18. 18.
    T. C. Foster, “Involvement of hippocampal synaptic plasticity in age-related memory decline,” Brain Res. Rev., 30, No. 2, 236–249 (1999).PubMedCrossRefGoogle Scholar
  19. 19.
    A. M. Watanabe and T. J. O’Dell, “Age-related changes in theta frequency stimulation-induced long-term potentiation,” Neurobiol. Aging, 24, No. 2, 267–272 (2003).CrossRefGoogle Scholar
  20. 20.
    C. M. Norris, S. Halpain, and T. C. Foster, “Reversal of age-related alterations in synaptic plasticity by blockade of L-type Ca2+ channels,” J. Neurosci., 18, No. 11, 3171–3179 (1998).PubMedGoogle Scholar
  21. 21.
    A. Kumar and T. C. Foster, “Enhanced long-term potentiation during aging is masked by processes involving intracellular calcium stores,” J. Neurophysiol., 91, No. 3, 2437–2444 (2004).PubMedCrossRefGoogle Scholar
  22. 22.
    J. W. Phillis, D. Song, and M. H. O’Reagan, “Effects of hyperglycemia on extracellular levels of amino acids and free fatty acids in the ischemic/reperfused rat cerebral cortex,” Brain Res., 837, No. 1, 177–183 (1999).PubMedCrossRefGoogle Scholar
  23. 23.
    G.-F. Tian and A. J. Baker, “Protective effect of high glucose against ischemia-induced synaptic transmission damage in rat hippocampal slices,” J. Neurophysiol., 88, No. 1, 236–248 (2002).PubMedGoogle Scholar
  24. 24.
    D. N. Alfarez, O. Weigert, M. Joels, and H. J. Krugers, “Corticosterone and stress reduce synaptic potentiation in mouse hippocampal slices with mild stimulation,” Neuroscience, 115, No. 4, 1119–1126 (2002).PubMedCrossRefGoogle Scholar
  25. 25.
    L. Xu, R. Anwyl, and M. J. Rowan, “Behavioral stress facilitates the induction of long-term depression in the hippocampus,” Nature, 387, No. 6632, 497–500 (1997).PubMedCrossRefGoogle Scholar
  26. 26.
    B. R. Christie, J. C. Magee, and D. Johnston, “The role of dendritic action potentials and Ca2+ in the induction of homosynaptic long-term depression in hippocampal CA1 pyramidal neurons,” Learn. Memory, 3, Nos. 2/3, 160–169 (1996).CrossRefGoogle Scholar
  27. 27.
    E. P. Kostyuk, U. V. Lalo, and P. G. Kostyuk, “Calcium signaling in cortical and thalamic neurons of rats with streptozotocin-induced diabetes,” Neurophysiology, 30, Nos. 4/5, 293–296 (1998).CrossRefGoogle Scholar
  28. 28.
    D. S. Kerr, L. W. Campbell, O. Tibault, and P. W. Landfield, “Hippocampal glucocorticoid receptor activation enhances voltage-dependent Ca2+ conductance: relevance to brain aging,” Proc. Natl. Acad. Sci. USA, 89, No. 18, 8527–8531 (1992).PubMedCrossRefGoogle Scholar
  29. 29.
    M. D. Smyth, J. P. Kesslak, B. J. Cummings, and C. W. Cotman, “Analysis of brain injury following intrahippocampal administration of beta-amyloid in streptozotocin-treated rats,” Neurobiol. Aging, 15, No. 2, 153–159 (1994).PubMedCrossRefGoogle Scholar
  30. 30.
    C. Pickering, L. Gustafsson, A. Cebere, et al., “Repeated maternal separation of male Wistar rats alters glutamate receptor expression in the hippocampus but not the prefrontal cortex,” Brain Res., 1099, No. 1, 101–108 (2006).PubMedCrossRefGoogle Scholar
  31. 31.
    M. Focking, I. Holker, and T. Trapp, “Chronic glucocorticoid receptor activation impairs CREB transcriptional activity in clonal neurons,” Biochem. Biophys. Res. Commun., 304, No. 4, 720–723 (2003).PubMedCrossRefGoogle Scholar
  32. 32.
    T. B. Franklin and T. S. Perrot-Sinal, “Sex and ovarian steroids modulates brain-derived neurotrophic factor (BDNF) protein levels in rat hippocampus under stressful and non-stressful conditions,” Psychoneuroendocrinology, 31, No. 1, 38–48 (2006).PubMedCrossRefGoogle Scholar
  33. 33.
    L. J. Kasselman, J. Kinter, A. Sideris, et al., “Dexamethasone treatment and ICAM-1 deficiency impair VEGF-induced angiogenesis in adult brain,” J. Vascul. Res., 44, No. 2, 283–291 (2007).CrossRefGoogle Scholar
  34. 34.
    I. I. Abramets, “Neurophysiological and neurochemical aspects of the effects of antidepressants and mood stabilizers,” Neurophysiology, 40, No. 1, 64–78 (2008).CrossRefGoogle Scholar
  35. 35.
    D. Tardito, J. Perez, E. Tiraboshi, et al., “Signaling pathways regulating gene expression, neuroplasticity, and neurotrophic mechanisms in the action of antidepressants: a critical overview,” Pharmacol. Rev., 58, No. 2, 115–134 (2006).PubMedCrossRefGoogle Scholar
  36. 36.
    J. A. Blendy, “The role of CREB in depression and antidepressant treatment,” Biol. Psychiat., 59, No. 6, 1144–1150 (2006).PubMedCrossRefGoogle Scholar
  37. 37.
    R. S. Duman and L. M. Monteggia, “A neurotrophic model for stress-related mood disorders,” Biol. Psychiat., 59, No. 6, 1116–1127 (2006).PubMedCrossRefGoogle Scholar
  38. 38.
    J. L. Warner-Schmidt and R. S. Duman, “VEGF is an essential mediator of the neurogenic and behavioral actions of antidepressants,” Proc. Natl. Acad. Sci. USA, 104, No. 5, 4647–4652 (2007).PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • Yu. V. Sidorova
    • 1
  • O. G. Obraztsova
    • 1
  • D. V. Evdokimov
    • 1
  • I. I. Abramets
    • 1
  • A. N. Talalaenko
    • 1
  1. 1.Donetsk National Medical University, Ministry of Public Health of UkraineDonetskUkraine

Personalised recommendations